The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site

描述（由申请人提供）：太平洋癌症研究联盟（PCRC）汇集了美国西部的社区癌症治疗中心，形成了一个NCI社区肿瘤研究计划（NCORP）社区站点。PCRC包括西雅图的瑞典癌症研究所及其前U10附属机构（普吉特海湾肿瘤联盟），波特兰的普罗维登斯波特兰医疗中心及其前社区临床肿瘤项目附属机构（西部肿瘤研究联盟），以及博伊西的山区肿瘤研究所。在多重PI/PD结构下，PCRC的3个主要组成部分将定义和促进临床试验和癌症护理交付研究议程，涉及华盛顿州、俄勒冈州、爱达荷州、阿拉斯加州和加利福尼亚州的24个参与组成部分和14个子组成部分。我们的每个主要组成部分都有数十年的癌症临床试验经验，并计划参与研究设计的各个方面，开展nci批准的临床研究和癌症护理交付研究，特别注重促进少数民族和服务不足人群参与我们的集水区域内所有研究类型和设置。提供生物标本库，在参与机构和我们的研究基地之间分享实践，并将基因组医学和靶向治疗纳入我们的研究能力组合。我们还计划建设

DESCRIPTION (provided by applicant): The Pacific Cancer Research Consortium (PCRC) brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. The PCRC includes Swedish Cancer Institute in Seattle and its former U10 affiliates (the Puget Sound Oncology Consortium), Providence Portland Medical Center in Portland and its former Community Clinical Oncology Program affiliates (the Western Oncology Research Consortium), and Mountain States Tumor Institute in Boise. Under a multiple PI/PD structure, the 3 primary components of the PCRC will define and facilitate the clinical trial and cancer care delivery research agenda across 24 participating components and 14 sub-components in Washington, Oregon, Idaho, Alaska, and California. Each of our primary component sites has decades of experience conducting clinical trials in cancer and plan to participate in all aspect of study design and conduct NCI-approved clinical studies and cancer care delivery research, with particular focus on facilitating the participation of minorities and underserved populations across all study types and settings within our catchment areas, providing bio specimen banking and sharing practices within the participating institutions and with our research bases, and incorporating genomic medicine and targeted therapies into our portfolio of research capabilities. We also plan to build a multicenter infrastructure and research agenda for cancer care delivery research to support the trials proposed by the NCTN, allowing us to participate in the development of novel approaches to CC DR studies.